The European Medicines Agency granted a PRIority MEdicines, or PRIME, designation for DNX-2401 as a treatment for recurrent glioblastoma. The PRIME designation was launched by the EMA in March to accelerate the regulatory approval of breakthrough therapies that target an unmet medical need. The objective is to provide patients who have few treatment options with...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
